Fdc Sales Mis Apr 2026

Arjun walked to the data entry cubicle. A young woman named Pooja was manually uploading scanned prescription forms from field force. He asked to see the originals for Dr. Iyengar’s forty scripts from week one.

“Yes sir, forty scripts. I saw them myself. She wrote them in front of me.”

Arjun stared at the glowing screen in his cubicle at 9:47 PM. The office was empty except for the janitor, who hummed an old Hindi film tune while mopping the corridor. On Arjun’s monitor, a cascade of numbers scrolled silently: units sold, doctor prescriptions, stockist balances, tertiary sales, secondary sales, primary sales.

And in the MIS, that whisper would never appear. Fdc Sales Mis

Someone was entering fake prescriptions into the system to game the CRM.

Arjun clicked into the MIS module that tracked prescription audits . The software was expensive, licensed from a US vendor, and meticulously built. It aggregated data from 1,200 chemists across his zone. Every time a bill was generated for Nebuflam-D, the system recorded it. Every time a doctor’s prescription was scanned at a pharmacy loyalty program, the system knew.

Arjun realized the MIS had no field for retailer anxiety . No column for patient self-medication . No variable for regulatory trauma . Arjun walked to the data entry cubicle

That was the first crack. In pharma, primary sales meant what the company sold to stockists. Secondary meant what stockists sold to retailers. Tertiary meant what retailers sold to patients. A beautiful primary number with a rotten tertiary was not success—it was a lie waiting to metastasize.

“Primary sales are strong,” his boss had said in the morning review. “But secondary is dead. The product is leaving our warehouse but not moving off pharmacy shelves.”

He walked out of the data entry room, past the janitor who had stopped humming, past the empty cubicles, past the motivational posters that said “Data is the new science.” Iyengar’s forty scripts from week one

“Arjun bhai, your Nebuflam-D is moving slow because the retailers are scared. Two months ago, the state drug controller banned another FDC—same steroid, different company. The wholesalers are still stuck with thirty lakhs of expired stock. So now, every time a retailer sees ‘low-dose steroid’ on a combo, they think: next ban . They order just one strip at a time. And the patient? If the doctor writes a combo, the patient asks the chemist, ‘Can I take just the expectorant alone?’ Then they buy half a course.”

A pause. “Sir, she said the combination gave some patients palpitations. She switched to separate molecules.”

Palpitations. The steroid component had a known but rare cardiac risk. In clinical trials, it occurred in 0.3% of patients. But if even one patient reported it to a senior doctor like Iyengar, she would blacklist the FDC forever. The MIS, however, would not capture why she stopped. It would only show a line descending. Numbers without stories were dangerous.

Arjun did something unorthodox. He opened the raw SQL database behind the MIS—the tables the dashboards were built on. He wrote a query to join prescriber data with patient redemption data with stockist return data . Then he looked at the time stamps.

He pulled up the prescription trend for Dr. Meera Iyengar, a pulmonologist in the city’s top lung hospital. Her prescription numbers for Nebuflam-D had gone from zero to forty in the first week—after his star rep had visited her thrice—and then dropped to two in the third week. But the MIS showed zero patient redemptions from her prescriptions. That meant either patients weren’t buying it, or the prescriptions were never written.